Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward Ltd. implemented a 1-for-12 reverse share split of its ordinary shares effective February 24, 2026. The move is intended to help the company meet the $1.00 minimum bid price required to keep its Nasdaq Capital Market listing.
The reverse split reduced issued and outstanding ordinary shares from 18,339,098 to approximately 1,528,098, while the company’s authorized ordinary shares increased from 75,000,000 to 100,000,000 under its Eighth Amended and Restated Articles of Association. No fractional shares were issued, with holdings rounded down to the nearest whole share, and the shares now trade on a split-adjusted basis under the existing symbol LFWD.
Lifeward Ltd. reported a change in its Board of Directors. On February 24, 2026, Class I director Hadar Levy notified the Board of his decision to step down, effective the same day. The company stated that his departure was not due to any disagreement regarding operations, policies or practices, and expressed gratitude for his service and contributions.
Lifeward Ltd. entered into an Intellectual Property Assignment and Technology Transfer Agreement with Skelable Ltd. on February 19, 2026. Lifeward will acquire specified intellectual property and related technology assets and bring certain key Skelable employees on board under new employment agreements.
As consideration, Lifeward will pay up to $500,000 in three milestone-based installments, with $480,000 payable in ordinary shares and $20,000 in cash. The shares will be priced at the higher of the prior trading day’s closing price or the daily volume-weighted average price. These shares will be issued as an unregistered offering relying on the Section 4(a)(2) exemption under the Securities Act of 1933. The initial closing of the transaction is expected to occur in the near future, subject to customary conditions.
Lifeward Ltd. entered into a new secured promissory note with Oramed Pharmaceuticals, Inc. for an initial principal amount of $525,000, which may be increased by up to an additional $975,000 upon mutual consent. This follows a prior secured promissory note for $3.0 million that remains outstanding.
The new note is secured by a lien on the company’s cash, carries interest at 24% per annum, and matures on the earlier of August 12, 2026 or the company’s failure to obtain shareholder approval for the transactions under the January 12, 2026 securities purchase and share purchase agreements. It includes customary covenants restricting additional indebtedness, liens, major transactions, and affiliate dealings, and defines standard events of default such as non-payment, covenant breaches, insolvency, and material adverse effects.
Upon default, Oramed may accelerate all obligations, increase the interest rate, terminate its commitments, and exercise contractual and legal remedies. Proceeds from the collateral will be applied ratably to Lifeward’s obligations under both the initial and subsequent secured promissory notes.
Lifeward Ltd. is asking shareholders to approve the acquisition of Oratech Pharma from Oramed and a related private placement that will significantly change its ownership and capital structure. Proposal 1 covers issuing approximately 131,297,754 ordinary shares in connection with the Oratech deal and associated warrants and convertible notes.
At closing, Oramed would receive ordinary shares and pre-funded warrants equal to 49.99% of Lifeward’s fully diluted equity, with no more than 45.00% issued as ordinary shares initially. Lifeward also agreed to senior secured convertible notes of $10 million plus an additional $10 million, convertible at $0.45 per share with 8% interest, and related warrants. Oramed is further entitled to a 4% revenue share on ReWalk product net revenue, capped by time, aggregate payments or a $200 million market capitalization trigger.
Shareholders will also vote on adding two external directors tied to the transaction, approving external director compensation, increasing shares under the 2025 incentive plan, granting equity to the CEO, and reappointing the independent auditor. Several proposals require both an ordinary majority and a special majority under Israeli law.
Lifeward Ltd. received an additional 180-day grace period from Nasdaq, until August 3, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company previously failed to meet this rule by the initial February 2, 2026 deadline.
Shareholders have already approved a reverse share split, and the board has set a 1-for-12 split ratio, with timing and implementation to be decided. Lifeward plans to monitor its share price and consider actions, including the approved reverse split, but notes there is no assurance it will regain compliance or avoid a potential delisting process.
Lifeward Ltd. is asking shareholders at a March 12, 2026 extraordinary meeting to approve a transformative acquisition of Oratech Pharma, Inc. and a related private financing package. The centerpiece is Proposal 1, authorizing the issuance of approximately 131,297,754 ordinary shares and multiple warrant and note instruments to Oramed Pharmaceuticals and certain investors.
In exchange for Oratech, Lifeward will issue to Oramed ordinary shares and pre-funded warrants equal to 49.99% of fully diluted equity at closing, with no more than 45.00% issued as ordinary shares immediately, plus additional warrants tied to net cash. Oramed and other investors will also receive up to $20 million of senior secured convertible notes and associated warrants, all initially convertible or exercisable at $0.45 per share and capped at 49.99% beneficial ownership. Lifeward also agrees to pay Oramed quarterly revenue-sharing of 4% of net ReWalk product revenue, subject to time and value caps, and to a 120‑day post-closing lock-up on shares held by Oramed and company insiders.
Lifeward Ltd. filed a report outlining governance changes tied to its planned transaction with Oramed Pharmaceuticals. The company now expects its board to expand to eight members upon closing of the Share Purchase Agreement, with three directors designated by Lifeward, three by Oramed, and two serving as External Directors under Israeli law.
Lifeward also called an Extraordinary General Meeting for March 12, 2026, and filed a preliminary proxy statement. Shareholders will be asked to approve a private placement of ordinary shares that would give Oramed at least 45.00%, and potentially more than 49.99%, of Lifeward’s outstanding voting power, a structure that may be deemed a Nasdaq “change of control” and is described as exempt from Israel’s special tender offer rules.
Lifeward Ltd. entered into a share purchase agreement to acquire all equity of Oratech Pharma from Oramed Pharmaceuticals. At closing, Lifeward will issue Ordinary Shares and pre-funded warrants to Oramed equal to 49.99% of its fully diluted equity, with Ordinary Shares capped at 45.00% of outstanding shares immediately after closing and the balance in pre-funded warrants subject to a 49.99% beneficial ownership cap. Additional transaction warrants will be issued based on Lifeward’s net cash at closing at an exercise price of $0.45 per share.
The deal also includes revenue sharing payments to Oramed equal to 4% of net revenue from ReWalk Personal Exoskeleton products until the earliest of 10 years after closing, receipt of a contractually defined maximum amount, or when Lifeward’s market capitalization reaches $200 million. Concurrently, Lifeward agreed to issue up to $20,000,000.00 of senior secured convertible notes bearing 8.0% interest, convertible at $0.45 per share, plus accompanying warrants, all subject to shareholder approval and ownership caps at 49.99%.
Lifeward Ltd. reported an insider equity award to one of its officers. The company granted 50,000 ordinary shares, par value NIS 1.75 per share, in the form of restricted stock units (RSUs) on December 11, 2025 under its 2025 Incentive Compensation Plan.
The RSUs vest ratably in four equal annual installments starting on the grant date, meaning the officer receives one quarter of the shares each year as they vest. The transaction is coded as an acquisition at a stated price of $0, reflecting an equity compensation award rather than a market purchase.
Following this grant, the reporting person beneficially owns 96,067 ordinary shares, held directly. The filing is made by a single reporting person, who serves as VP of Market Access & Strategy at Lifeward Ltd.